About the latest price and purchase methods of Penpulimab

Penpulimab (Penpulimab), as a new PD-1 immune checkpoint inhibitor, has been approved in China for the treatment of relapsed or refractory classic Hodgkin lymphoma (cHL), especially for adult patients who have relapsed or progressed after at least two systemic treatments. In addition, penpilimab is also actively promoting clinical research in the treatment of other tumor types such as recurrent or metastatic nasopharyngeal carcinoma (NPC) and non-small cell lung cancer (NSCLC). Some indications are undergoing registration review, and the indications are expected to be further expanded in the future. Panpilimabcan relieve T cell inhibition by precisely regulating the immune system and activating the body's natural immune response against cancer cells. Therefore, it has shown good efficacy and safety in the treatment of refractory and recurrent tumors.

In terms of price, the specifications of penpilimab currently sold in the domestic market are100mg (10mL)/box, and the price of each box is approximately RMB 4,000. The specific price fluctuates depending on the region and medical institution. It should be noted that although it has been officially launched in China, in overseas markets, including the United States, Europe, Australia and other regions, amprilimab is still in the clinical trial stage or review stage and has not yet been officially approved for marketing. Therefore, the overseas commercial sales price has not yet been determined. At present, if patients need to purchase penpilimab, the main way is to purchase the drug after issuing a prescription through the oncology department or hematology department of large domestic hospitals. Some oncology hospitals and pharmacies can also provide related drugs.

It is worth noting that penpilimab is not currently fully included in the national medical insurance catalog, so patients need to bear the cost of the drug themselves. However, some regions and medical institutions may open charity assistance programs or drug assistance programs for specific patients. Patients can consult through the hospital or official channels to find out whether they meet the relevant application conditions to reduce the burden of treatment.

Reference materials:https://www.promab.com/products/primary-antibody/monoclonal-antibody